No Data
Chordia Therapeutics, Simbio Pharmaceuticals, etc.
<190A> Chordia Therapeutics Co., Ltd. SBI Investment Co., Ltd. shareholding ratio 6.42% → 8.73% Reporting obligation start date 2024/07/18 <202A> Mamezou Digital Holdings Co., Ltd. Mamezou K2 Top Holdings Co., Ltd. shareholding ratio 71.78% → 67.99% Reporting obligation start date 2024/07/24 <2164> Regional Newspaper Co., Ltd. Engi Co., Ltd.
Insider decrases its stake in SymBio Pharmaceuticals(4582.JP) to 4.18%
On Jul 25, ハイツ・キャピタル・マネジメント・インク submitted the Change Report to Ministry of Finance. The report shows that ハイツ・キャピタル・マネジメント・インク decreased their holdings in $SymBio Pharmaceuticals(4582.JP)$, with
The Tokyo Stock Exchange's 250 Gross Market Index fell sharply and expanded its decline due to the pullback of large cap stocks, although it rebounded.
Tokyo Stock Exchange growth market index is at 836.81, down 14.26, with a volume of 98.64 million shares and a turnover of JPY 132.1 billion. Tokyo Stock Exchange Growth Market 250 Index is at 648.21, down 12.69, with a volume of 62.32 million shares and a turnover of JPY 90.3 billion. Today's growth market saw significant declines in both the Tokyo Stock Exchange growth market index and the Tokyo Stock Exchange Growth Market 250 Index. There were 144 advancing stocks, 412 declining stocks, and 28 unchanged stocks. On the 23rd, the US stock market fell, with the Dow Jones Industrial Average dropping by 57.35 dollars.
The Tokyo Stock Exchange Growth Market Index fell for the third day, and overall weakness was evident in the growth market on the first day.
The Tokyo Stock Exchange Growth Market Index is at 846.29, down 21.50 with a volume of 0.22538 billion shares and a turnover of JPY 121.6 billion. The Tokyo Stock Exchange Growth Market 250 index is at 657.25, down 18.48, with a volume of 0.13369 billion shares and a turnover of JPY 95.8 billion. In today's Growth Market, the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index have fallen for three consecutive business days. There are 124 advancing stocks, 432 declining stocks, and 28 unchanged. On the 19th in the US market, the Dow average fell by 377.49 dollars.
Pay attention to the movements of Biotechnology which fell sharply over the weekend and the battle of the 200-day moving average in the Growth 250 Index.
- Pay attention to whether the emerging markets can maintain the level of the 200-day moving average this week, which seems to be more stable than the prime market, which is shaken by former President Trump's words and actions. We want to pay attention to whether both the Tokyo Growth Market Index and the Tokyo Growth 250 Index can maintain the level of the 200-day moving average. Although the Russell 2000 index, which was a stimulus material for the current emerging markets, has stopped rising, we believe that the small and mid-cap stocks will continue to be strong in the US market compared to the major stock price indices such as NY Dow and Nasdaq. - Focus of buying
Emerging market outlook: Pay attention to the battle of the growth 250 index on the 200-day line and the trend of the bio-related stock that plummeted over the weekend.
Despite the dominance of buying, emerging markets saw a slight decline on a weekly basis. During the same period, while the Nikkei Average fell by -2.74%, the growth market index fell by -0.10% and the growth market 250 index fell by -0.21%, making the emerging markets a steady market. After the holidays, the Russell 2000 index, which is composed mainly of small and medium-sized companies on the US market, continued to rise, which stimulated buying of leading stocks in the growth market and bio-related stocks. Tokyo Stock Exchange
No Data
